The first person is vaccinated with Nanocovax, a made-in-Vietnam vaccine, at the Military Medical Academy on December 17. (Photo: VNA)Hanoi (VNA) – The first human trial of
vaccine Nanocovax began in Vietnam on December 17 with the first three
volunteers, one man and two women aged 20-25, receiving injections at the
Military Medical Academy.
Nanocovax, developed by the Nanogen Pharmaceutical
Biotechnology JSC, is the first Vietnam-made COVID-19 vaccine to enter human
trials, with another two from other manufacturers to follow in February and
March 2021.
The first candidates are among 60 volunteers, aged 18-50,
selected for the first phase of the vaccine trials. They are divided into three
groups for receiving three doses of 25 mcg, 50 mcg and 75 mcg.
With safety staying first in vaccine clinical trials, the
first volunteers received the minimum dose of 25 mcg. They will stay at separate
rooms at the Military Medical Academy for the first 72 hours for medical
assessment. They will continue to be closely monitored at their residences for
the next 56 days.
A team of more than 40 medical experts has been set up to
deal with unwanted side effects after the vaccination.
Prof. Dr. Do Quyet, Director of the Military Medical Academy, speaks to the press following the trial vaccination. (Photo: VNA)
“In the world, there have been very few vaccine trials
with unexpected reactions, and we hope vaccine is no exception,” said
Prof. Dr. Do Quyet, Director of the Military Medical Academy.
“To ensure the highest safety for the volunteers, we had
to best prepare, even for the life-threatening circumstances,” he said.
“We pledge to assess [the vaccine] objectively, honestly,
and transparently, and submit the proposals to the health ministry for
later-stage trials,” he continued./.
Source: VietnamPlus
